In recent years, the health care industry in the U.S. has accelerated its shift from fee-for-service toward value-based care (VBC) models, focused on holistic, long-term outcomes for patients and lower costs for the system. This shift was spearheaded by the Centers for Medicare and Medicaid (CMS) through legislation enacted between 2008 and 2019, notably by
The COVID-19 crisis will eventually move past its peak and everyday life will phase into a new normal. When it does, it’s unlikely that customers or businesses will go back to their pre-pandemic ways. As “essential” businesses, retail pharmacies were some of the first to experience and respond to new changes in customer behaviors and
Pharmacies have long been the front door to the country’s health care system. People choose their favorite pharmacy and make stopping by a habit. They drop in to pick up monthly prescriptions, ask the pharmacist for advice and, of course, snag retail items in the process. But can pharmacies hold on to this coveted position?
In today’s retail landscape filled with intense competition and discouraging news about store closures and challenging sales figures, Global Market Development Center (GMDC)|Retail Tomorrow is focused on designing new strategies for retailers and suppliers to navigate a path forward to evolve and thrive. Even during one of the industry’s most uncertain times, brick-and-mortar still has
In recent years, the specialty pharmacy industry has been defined by rapid growth with considerable entry from new participants. Factors driving growth include an increase of therapies introduced into the pharmacy benefit class rather than through the medical benefit, a growing number of patients receiving treatment for a wider range of conditions, price inflation caused
Every year, Canadians, who have access to one of the most advanced health care systems in the world, spend more than $200 billion on health care, $34 billion of which is on pharmaceuticals. Although medical services are socialized, government-supported drug benefits are limited to children, the elderly and the poor. In this regard, drug funding
